gsk201601156k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending January 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 15 January 2016 that the following Directors and Persons Discharging Managerial Responsibilities acquired GSK Ordinary Shares ('Shares') on 14 January 2016, at a price of 1368.87 pence per Share, as a result of the reinvestment of dividends paid on Shares held through GSK's ShareReward Plan (the 'Plan'):
|
Director/PDMR
|
Ordinary Shares
|
|
Sir Andrew Witty
|
43
|
|
Mr R G Connor
|
53
|
|
Mr S Dingemans
|
15
|
|
Mr N Hirons
|
3
|
|
Mr S A Hussain
|
10
|
|
Mr D S Redfern
|
61
|
|
Ms C Thomas
|
61
|
|
Mr P C Thomson
|
31
|
|
Dr P J T Vallance
|
35
|
|
Ms E Walmsley
|
10
|
|
Mrs V A Whyte
|
42
|
V A Whyte
Company Secretary
15 January 2016
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: January 15, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc